ArticleFrontiers in immunology2026
Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Proton pump inhibitor (PPI) use has been associated with reduced immune checkpoint inhibitor (ICI) efficacy in metastatic non-small cell lung cancer (mNSCLC) with evidence limited to their use during a short time period around ICI initiation. This study evaluated the associations between the timing and intensity of PPI exposure up to one year before ICI initiation and overall survival (OS) in mNSCLC patients treated with ICIs. Methods: This retrospective cohort study included consecutive mNSCLC patients treated with ICIs within routine clinical practice. Patients were grouped by the timing of PPI exposure from 365 days before to 30 days after (-365 to +30 days) ICI initiation: (1) no PPIs within -365 to +30 days; (2) PPIs only within -365 to -31 days; and (3) PPIs also within ±30 days of ICI initiation. The intensity of PPI exposure was quantified with the total defined daily doses (DDDs). OS was estimated using Kaplan-Meier methods, and associations between PPI exposure and OS were analyzed using Cox proportional hazards models. Results: Of 391 patients included (median age 64.7 years, 58.6% male), 73.4% had access to PPI within -365 to +30 days of ICI initiation. PPI exposure within ±30 days (220 patients) was associated with reduced median OS (mOS) compared with no PPI exposure between -365 and +30 days of ICI initiation (mOS 15.4 vs 21.9 months; adjusted hazard ratio [aHR] 1.373, 95% CI 1.007-1.873, p = 0.045). High-intensity PPI exposure within -365 to +30 days of ICI initiation (DDD > 159; 108 patients) was also associated with reduced mOS compared with no PPI exposure in this period (mOS 13.4 vs 21.9 months; aHR 1.454, 95% CI 1.023-2.067, p = 0.037). Discussion: PPI use around ICI initiation as well as PPI treatment intensity over a wider period was associated with reduced OS. Efforts should be made to streamline PPI use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.